证券代码：603657 证券简称:春光科技 公告编号：2025-023 金华春光橡塑科技股份有限公司 股票交易异常波动及风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 金华春光橡塑科技股份有限公司（以下简称"公司"或"春光科技"）股票 于 2025 年 5 月 8 日、2025 年 5 月 9 日连续二个交易日内收盘价格涨幅偏离值累计 超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动 情形。 ? 经公司自查并向控股股东及实际控制人书面发函核实，截至本公告披露日， 确认不存在应披露而未披露的重大事项或重要信息。 ? 公司提醒投资者注意投资风险，公司股价短期波动较大，敬请广大投资者注 意二级市场交易风险，理性决策，审慎投资。 一、股票交易异常波动的具体情况 公司股票于 2025 年 5 月 8 日、2025 年 5 月 9 日连续二个交易日内收盘价格涨 幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票 交易异常波动情形。 二、公司关注并核实的 ...

Core Viewpoint - The stock of Chunguang Technology (603657.SH) experienced abnormal trading fluctuations, with a cumulative price increase deviation exceeding 20% over two consecutive trading days on May 8 and May 9, 2025 [1] Group 1: Stock Performance - As of May 9, 2025, the stock turnover rate reached 17.06%, and the cumulative turnover rate from April 30 to May 9, 2025, was 33.60% [1] - The company has a relatively small external circulation, with the controlling shareholder, actual controller, and concerted actors holding a total of 90,978,100 shares, accounting for 66.68% of the total share capital [1] Group 2: Market Conditions - The company's fundamentals have not changed, indicating a potential risk of irrational market speculation [1]

●亚振家居股份有限公司（以下简称"公司"）股票于2025年5月6日、7日、8日连续三个交易日内日收盘 价格涨幅偏离值累计达到12%，属于股票交易异常波动。 ●生产经营风险。公司2024年度经审计的扣除非经常性损益后的净利润为负值，且扣除与主营业务无关 的业务收入和不具备商业实质的收入后的营业收入低于3亿元，触及《上海证券交易所股票上市规则》 第9.3.2条第一款第（一）项规定，公司股票于2025年5月6日起实施退市风险警示。公司2025年第一季度 营业总收入为4,067.57万元（未审计），归属于上市公司股东的净利润为-2,131.38万元，归属于上市公 司股东的扣除非经常性损益的净利润为-2,047.67万元（未审计）。 ●经公司自查，并书面征询控股股东及实际控制人，截至本公告披露日，除上述控制权变更事项外，确 认不存在应披露而未披露的重大事项和风险事项。 登录新浪财经APP 搜索【信披】查看更多考评等级 一、股票交易异常波动的具体情况 证券代码：603389 证券简称：*ST亚振 公告编号：2025-021 亚振家居股份有限公司 股票交易异常波动暨风险提示公告 本公司董事会及全体董事保证本公告内容不存在任 ...

航天南湖发布股票交易异常波动公告，经公司自查并向控股股东及实际控制人核实，不存在应披露而未 披露的重大信息。公司股价短期波动幅度较大，敬请广大投资者注意二级市场交易风险，理性决策，审 慎投资。 ...

Group 1 - The company's stock (ST Ruihe; stock code: 002620) experienced an abnormal trading fluctuation, with a cumulative closing price deviation exceeding 12% over three consecutive trading days on April 30, May 6, and May 7, 2025 [1] - The company confirmed that there are no undisclosed significant matters that could impact the stock price, and previous disclosures do not require correction or supplementation [3][5] - During the period of abnormal stock fluctuation, the company's controlling shareholder and actual controller did not engage in buying or selling the company's stock [4] Group 2 - The company is currently facing a restructuring application from a creditor due to its inability to repay debts, but it has not yet received any court acceptance documents regarding this application [2] - The company has confirmed that it will continue to manage its daily operations and closely monitor the situation regarding the restructuring application [2] - The company has a net asset value of 40.62 million yuan as of December 31, 2024, with 161 bank accounts frozen, totaling 149.25 million yuan [7]

4连板精进电动公告，公司股票交易连续10个交易日内收盘价格涨幅偏离值累计超过100%，属于股票交 易严重异常波动。经自查并向控股股东、实际控制人核实，不存在应披露而未披露的重大信息。公司年 度及季度仍处于亏损状态，敬请广大投资者注意二级市场交易风险，避免跟风炒作，理性决策，审慎投 资。 ...

Group 1 - The company will participate in the "2024 Annual Performance Briefing and Investor Reception Day" on May 13, 2025, to enhance communication with investors regarding its annual report and other key topics [1] - The company has received marketing authorization from the Therapeutic Goods Administration (TGA) in Australia for its injectable drug Bivalirudin, which is indicated as an anticoagulant for high-risk acute coronary syndrome patients [3][4] - The injectable Bivalirudin has previously received approvals from various regulatory bodies, including the FDA in the United States and the Saudi Arabian SFDA [5] Group 2 - The company's stock has experienced abnormal trading fluctuations, with a cumulative price deviation exceeding 12% over two consecutive trading days [9] - The company has confirmed that there are no undisclosed significant matters that could affect its stock price, and it has conducted a thorough review of its recent trading activity [10][11] - The company has been placed under a delisting risk warning due to negative financial results, with the lowest of its audited profit total, net profit, and net profit after non-recurring gains and losses being negative, and revenue below 300 million [12]

迪生力（603335）公告，公司股票于2025年4月29日、4月30日、5月6日连续3个交易日内收盘价格涨幅 偏离值累计超过20%，属于股票交易异常波动情形。控股股东江门力鸿投资有限公司于5月6日减持公司 股份57.53万股，平均股价为4.93元，当日减持总金额为283.62万元。 ...

Core Viewpoint - Hubei Jiuyou Investment Co., Ltd. has experienced significant stock price fluctuations, with a cumulative decline of over 12% in three consecutive trading days, raising concerns about potential delisting due to financial issues [2][3][9]. Group 1: Stock Trading Anomalies - The company's stock price fell significantly on April 25, April 28, and April 29, 2025, with a cumulative price deviation of over 12%, indicating abnormal trading activity [2][3]. - On April 29, 2025, the stock closed at 0.96 yuan, marking the first time it fell below 1 yuan, which triggers a risk warning regarding potential delisting [2][9]. Group 2: Financial Audit and Reporting - The auditing firm Zhongxing Caiguanghua issued an audit report with a disclaimer of opinion for the company's 2024 financial statements, indicating the company has reached a financial delisting condition [2][9][11]. - The company has been notified by the Shanghai Stock Exchange regarding the potential termination of its stock listing due to the audit findings [11][15]. Group 3: Company Operations and Management - Despite the stock price fluctuations, the company reported that its production and operational activities remain normal, with no significant changes in its main business [4]. - The company confirmed that there are no undisclosed significant events that could impact stock prices, including major asset restructuring or debt reorganization [5][7]. Group 4: Regulatory Compliance and Future Actions - The company is required to disclose risks associated with the potential delisting and must ensure compliance with relevant regulations during this process [12][13]. - The company must appoint a sponsor to facilitate the transition to the National Equities Exchange and Quotations system within 45 trading days after delisting [12][16].

重要风险提示： 1、公司于2025年1月18日在《中国证券报》《证券时报》和巨潮资讯网（www.cninfo.com.cn）披露了 《2024年度业绩预告》（公告编号：2025-003）。经公司财务部门初步测算（未经审计），预计公司 2024年度归属于上市公司股东的净利润为负值，且扣除后营业收入为14,000万元至18,000万元。根据 《深圳证券交易所股票上市规则》的相关规定，公司股票交易将在2024年年度报告披露后可能被实施退 市风险警示（股票简称前冠以"*ST"字样）。敬请广大投资者注意投资风险。 2、股票异常波动风险 公司分别于2025年4月15日、2025年4月17日披露《股票交易异常波动及风险提示性公告》（公告编号： 2025-015、2025-016）。公司股票（证券简称：双成药业，证券代码：002693）收盘价格涨幅偏离值累 计达到深圳证券交易所的有关规定属于股票交易异常波动情况。近期，公司股票交易价格发生较大波 动，敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载 ...